Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% – Still a Buy?

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) rose 3.1% on Tuesday . The company traded as high as $13.80 and last traded at $13.80. Approximately 8,827 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 41,049 shares. The stock had previously closed at $13.39.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.

Greenwich LifeSciences Stock Up 3.1 %

The business’s 50 day simple moving average is $14.07 and its 200 day simple moving average is $14.52. The stock has a market cap of $177.74 million, a price-to-earnings ratio of -19.17 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). Equities research analysts forecast that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 5,500 shares of the business’s stock in a transaction on Monday, August 5th. The stock was acquired at an average price of $13.18 per share, with a total value of $72,490.00. Following the acquisition, the chief executive officer now directly owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have acquired 8,800 shares of company stock valued at $120,665. 52.86% of the stock is owned by insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the 2nd quarter valued at $264,000. Rhumbline Advisers bought a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $117,000. Finally, Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after acquiring an additional 1,420 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.